SLC5A2 and diabetes mellitus: In patients with concomitant type 2 diabetes, SGLT2 inhibitor use was associated with a significantly slower eGFR decline compared with dipeptidyl peptidase-4 inhibitors during the same period (difference: +1.29 ml/min per 1.73 m2/90 d), suggesting potential benefit in individuals where diabetes and cardiovascular comorbidities may contribute more prominently to kidney disease progression.68